Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday's announcement aligns with these preferences, which investors may view positively.On Tuesday, QuidelOrtho Corporation (NASDAQ:QDEL) priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
周二，窥得儿医药公司（纳斯达克:QDEL）定价了卡莱尔六号凯曼控股之前宣布的826万股的次级发行。
The selling stockholder will receive all of the proceeds. The company is not selling any shares.
出售股东将收到所有收益。公司不出售任何股份。
The last reported sale price of QuidelOrtho's common stock on Nov. 19 was $38.58 per share. Goldman Sachs & Co. LLC is acting as the sole underwriter.
窥得儿医药普通股11月19日的最近报价为每股38.58美元。高盛及其附属公司充当唯一承销商。
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday's announcement aligns with these preferences, which investors may view positively.
威廉·布莱尔（William Blair）分析师指出，卡莱尔在今年夏天早些时候通过较小的交易出售了部分股份。 那时，投资者建议卡莱尔通过大宗交易或次级交易进行进一步出售。 周二的公告符合这些偏好，投资者可能会积极看待。
While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
尽管一些人可能会解释这一举动是对窥得儿医药持续改善缺乏信心的表现，但分析师并不认同这种观点。
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
相反，他们强调考虑卡莱尔的长期持有期等因素，因为该公司最初于2014年收购了奥莱化验（Ortho Clinical）。
William Blair analysts write, "We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name."
威廉·布莱尔分析师写道：“我们认为这对股票是长期净利好，因为它消除了投资者在关于该公司的交谈中出现的部分顾虑。”
William Blair reiterates a Market Perform rating.
威廉·布莱尔重申市场表现评级。
Price Action: QDEL stock is down 4.2% at $36.96 at last check Wednesday.
价格走势：窥得儿医药股票最新交易价为36.96美元，周三最后查看时下跌了4.2%。
- Salesforce Tool Aims To Simplify AI Agent Testing, Deployment
- 赛富时工具旨在简化人工智能代理的测试和部署
Photo: Shutterstock
Photo: shutterstock
